高尔基体分泌型聚集素的表达在肝细胞癌进展中的作用

郑文杰; 姚登福

doi:10.3969/j.issn.1001-5256.2014.03.022

高尔基体分泌型聚集素的表达在肝细胞癌进展中的作用

DOI: 10.3969/j.issn.1001-5256.2014.03.022

南通大学附属医院临床医学研究中心

基金项目:

国家国际科技合作项目(2013DFA32150)；江苏省临床医学专项(BL2012053)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2667
- HTML全文浏览量: 15
- PDF下载量: 642
- 被引次数: 0
出版历程
- 出版日期: 2014-03-20

Role of Golgi secretory clusterin expression in progression of hepatocellular carcinoma

Research funding:

摘要

摘要:
肝细胞癌(HCC)是连续、多中心、多病因的发展过程。现今已有多种药物投入HCC临床试验,但因其具有高侵袭和高转移能力,预后并不理想。阐述了聚集素(CLU)的结构特点及生物学特性;介绍了分泌型聚集素(sCLU)与HCC发生发展关系的研究进展,指出聚集素过表达可促进肝癌转移,诱导上皮间质转换,抑制肝癌细胞凋亡并可导致耐药。此外简介了第二代反义核酸药物Custirsen的分子结构,在体外可下调HCC侵袭能力。提出sCLU可从多方面促进HCC的发生发展,其分子机制值得进一步探究。
- 癌,肝细胞 /
- 高尔基体 /
- 聚集素 /
- 综述
Abstract:
Hepatocellular carcinoma ( HCC) is a progressive, multi- center, and multi- cause disease. Nowadays, numerous drugs have been investigated in clinical trials for treatment of HCC, but the prognosis was usually poor because HCC is highly invasive and metastatic. The structural characteristics and biological properties of clusterin ( CLU) are described; the research progress in relationship of secretory CLU ( sCLU) with the development and progression of HCC is summarized, and it is pointed out that the overexpression of CLU may promote cancer metastasis, induce epithelial- mesenchymal transition, inhibit apoptosis of HCC cells, and lead to resistance to chemotherapy drugs. In addition, the molecular structure of second- generation antisense nucleic acid drug Custirsen, which may downregulate the metastasis of HCC in vitro, is briefly presented. It is suggested that sCLU promotes the development and progression of HCC in many ways and deserves further research for its molecular mechanism of action.
- carcinoma, hepatocellular /
- golgi apparatus /
- clusterin /
- review

HTML全文

参考文献(21)

[1]AYUB A, ASHFAQ UA, HAQUE A.HBV induced HCC:major risk factors from genetic to molecular level[J].Biomed Res Int, 2013, 2013:810461.

[2] JEMAL A, BRAY F, CENTER M, et al.Global cancer statistics[J].CA Cancer J Clin, 2011, 61 (2) :69-90.

[3] LAU SH, SHAM JS, XIE D, et al.Clusterin plays an important role in hepatocellular carcinoma metastasis[J].Oncogene, 2006, 25 (8) :1242-1250.

[4]NAFEE AM, PASHA HF, ABD SM, et al.Clinical significance of serum clusterin as a biomarker for evaluating diagnosis and metastasis potential of viral-related hepatocellular carcinoma[J].Clin Biochem, 2012, 45 (13-14) :1070-1074.

[5]JUN CH, SIM DW, KIM SH, et al.Predictive factors for recurrence and survival in hepato-cellular carcinoma in South Korea[J].Anticancer Res, 2013, 33 (9) :4129-4134.

[6]LIU XL, LI FQ, LIU LX, et al.TNF-α, HGF and macrophage in peritumoural liver tissue relate to major risk factors of HCC recurrence[J].Hepatogastroenterology, 2013, 60 (125) :1121-1126.

[7]TROUGAKOS IP, DJEU JY, GONOS ES, et al.Advances and challenges in basic and translational research on clusterin[J].Cancer Res, 2009, 69 (2) :403-406.

[8]WYATT AR, YERBURY JJ, BERGHOFER P, et al.Clusterin facilitates in vivo clearance of extra-cellular misfolded proteins[J].Cell Mol Life Sci, 2011, 68 (23) :3919-3931.

[9]NOVINEC M, LENARCˇICˇB, BAICI A.Clusterin is a specific stabilizer and liberator of extracellular cathepsin K[J].FEBS Lett, 2012, 586 (7) :1062-1066.

[10]LAU SH, SHAM JS, XIE D, et al.Clusterin plays an important role in hepatocellular carcinoma metastasis[J].Oncogene, 2006, 25 (8) :1242-1250.

[11]COMUNALE MA, WANG M, RODEMICH-BETESH L, et al.Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma[J].Cancer Epidemiol Biomarkers Prev, 2011, 20 (6) :1222-1229.

[12] NAFEE AM, PASHA HF, ABD EL AAL SM, et al.Clinical significance of serum clusterin as a biomarker for evaluating diagnosis and metastasis potential of viral-related hepatocellular carcinoma[J].Clin Biochem, 2012, 45 (13-14) :1070-1074.

[13]WANG Y, LIU YH, MAI SJ, et al.Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis[J].J Gastroenterol Hepatol, 2010, 25 (6) :1123-1128.

[14]LIU X, WAN X, LI Z, et al.Golgi protein 73 (GP73) , a useful serum marker in liver diseases[J].Clin Chem Lab Med, 2011, 49 (8) :1311-1316.

[15]TROUGAKOS IP, LOURDA M, ANTONELOU MH, et al.Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex[J].Clin Cancer Res, 2009, 15 (1) :48-59.

[16]WANG C, JIANG K, GAO D, et al.Clusterin protects hepatocellular carcinoma cells from endoplasmic reticulum stress induced apoptosis through GRP78[J].PLoS One, 2013, 8 (2) :e55981.

[17]ZOUBEIDI A, CHI K, GLEAVE M.Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer[J].Clin Cancer Res, 2010, 16 (4) :1088-1097.

[18]XIU P, DONG X, DONG X, et al.Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma[J].Cancer Sci, 2013, 104 (3) :375-382.

[19]WANG C, JIANG K, KANG X, et al.Tumor-derived secretory clusterin induces epithelial-mesenchymal transition and facilitates hepatocellular carcinoma metastasis[J].Int J Biochem Cell Biol, 2012, 44 (12) :2308-2320.

[20]PORSCH H, BERNERT B, MEHIC'M, et al.Efficient TGFβ-induced epithelial-mesenchymal transition depends on hyaluronan synthase HAS2[J].Oncogene, 2013, 32 (37) :4355-4365.

[21]YAN XD, DONG ZZ, YAO DF.Abnormal activation of insulinlike growth factor-I receptor in hepatocellular carcinoma and potential of IGF-IR targeted therapy[J].J Clin Hepatol, 2013, 29 (6) :473-476. (in Chinese) 严晓娣, 董志珍, 姚登福.胰岛素样生长因子-I受体异常激活与肝癌靶向治疗[J].临床肝胆病杂志, 2013, 29 (6) :473-476.

施引文献

资源附件(0)

访问统计